110 related articles for article (PubMed ID: 36420767)
1. Direct evidence gap on fixed versus adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: Systematic review and individual patient data meta-analysis.
Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Villar JC; Reidel S; Gibbons L; Sosa-Estani S
Trop Med Int Health; 2023 Jan; 28(1):2-16. PubMed ID: 36420767
[TBL] [Abstract][Full Text] [Related]
2. Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Ribeiro I; Villar JC; Sosa-Estani S
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008529. PubMed ID: 32804966
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
5. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
6. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.
Villar JC; Perez JG; Cortes OL; Riarte A; Pepper M; Marin-Neto JA; Guyatt GH
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003463. PubMed ID: 24867876
[TBL] [Abstract][Full Text] [Related]
7. Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol.
Cafferata ML; Toscani MA; Althabe F; Belizán JM; Bergel E; Berrueta M; Capparelli EV; Ciganda Á; Danesi E; Dumonteil E; Gibbons L; Gulayin PE; Herrera C; Momper JD; Rossi S; Shaffer JG; Schijman AG; Sosa-Estani S; Stella CB; Klein K; Buekens P
Reprod Health; 2020 Aug; 17(1):128. PubMed ID: 32831069
[TBL] [Abstract][Full Text] [Related]
8. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
[TBL] [Abstract][Full Text] [Related]
9. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.
Martí-Carvajal AJ; Kwong JS
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD009077. PubMed ID: 27388039
[TBL] [Abstract][Full Text] [Related]
11. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.
Villar JC; Marin-Neto JA; Ebrahim S; Yusuf S
Cochrane Database Syst Rev; 2002; (1):CD003463. PubMed ID: 11869663
[TBL] [Abstract][Full Text] [Related]
12. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.
Torrico F; Gascón J; Barreira F; Blum B; Almeida IC; Alonso-Vega C; Barboza T; Bilbe G; Correia E; Garcia W; Ortiz L; Parrado R; Ramirez JC; Ribeiro I; Strub-Wourgaft N; Vaillant M; Sosa-Estani S;
Lancet Infect Dis; 2021 Aug; 21(8):1129-1140. PubMed ID: 33836161
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.
Olivera MJ; Cucunubá ZM; Valencia-Hernández CA; Herazo R; Agreda-Rudenko D; Flórez C; Duque S; Nicholls RS
PLoS One; 2017; 12(9):e0185033. PubMed ID: 28949997
[TBL] [Abstract][Full Text] [Related]
14. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Bourke JP; Bueser T; Quinlivan R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
[TBL] [Abstract][Full Text] [Related]
15. Nanoencapsulation of benznidazole in calcium carbonate increases its selectivity to Trypanosoma cruzi.
Tessarolo LD; de Menezes RRPPB; Mello CP; Lima DB; Magalhães EP; Bezerra EM; Sales FAM; Barroso Neto IL; Oliveira MF; Dos Santos RP; Albuquerque EL; Freire VN; Martins AM
Parasitology; 2018 Aug; 145(9):1191-1198. PubMed ID: 29642963
[TBL] [Abstract][Full Text] [Related]
16. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole.
Franco LAM; Moreira CHV; Buss LF; Oliveira LC; Martins RCR; Manuli ER; Lindoso JAL; Busch MP; Pereira AC; Sabino EC
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669428
[TBL] [Abstract][Full Text] [Related]
18. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
[TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
20. The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform.
Maguire BJ; Dahal P; Rashan S; Ngu R; Boon A; Forsyth C; Strub-Wourgaft N; Chatelain E; Barreira F; Sosa-Estani S; Guérin PJ
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009697. PubMed ID: 34398888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
